Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska Alaska Tuberculosis Program Manual - Epidemiology - State of Alaska
References 1 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):15. 2 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):40. 3 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):1. 4 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):4–5; CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):7–9, 22. 5 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):8–9. 6 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):1–2. 7 CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000;49(No. RR-6):1. 8 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):40. 9 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):40. 10 ATS, CDC, IDSA. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005;54(No. RR-12):40. 11 CDC. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR 2005;54(No. RR-17):10. A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L Targeted Testing for Latent Tuber culosis Infection 3.9 R e v i s e d N o v e m b e r 2 0 1 2
B Notifications CONTENTS Introduction ............................................. 4.2 Purpose................................................................ 4.2 Pre-arrival medical screening for tuberculosis ..... 4.2 Overseas screening of applicants for immigration .......................................................... 4.4 Policy ................................................................... 4.6 Follow-up of B1 and B2 Tuberculosis Arrivals ............................. 4.7 Division of Global Migration and Quarantine forms .................................................................... 4.7 Electronic disease notification process overview ............................................................... 4.7 Patient follow-up .................................................. 4.8 Evaluation of B1, B2, and B Tuberculosis Arrivals ............................. 4.9 Evaluation activities ............................................. 4.9 Treatment ........................................................... 4.11 Resources and References ................. 4.12 A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L B Notifications 4.1 Revised November 2012
- Page 5 and 6: Monthly assessment of adherence ...
- Page 7 and 8: When to Expand a Contact Investigat
- Page 9 and 10: Introduction CONTENTS About the Ala
- Page 11 and 12: How to Use This Manual Portable Doc
- Page 13 and 14: Printing To access the print dialog
- Page 15 and 16: Abbreviations Refer to the list bel
- Page 17 and 18: QFT QuantiFERON ® -TB test QFT-G Q
- Page 19 and 20: Alaska Statutes and Regulations on
- Page 21 and 22: National and State Program Objectiv
- Page 23 and 24: Indicator 3 Thorough contact invest
- Page 25 and 26: National Standards and Recommendati
- Page 27 and 28: Roles and Responsibilities Contact
- Page 29 and 30: Local Public Health Agencies Table
- Page 31 and 32: Resources and References Resources
- Page 33 and 34: Introduction Purpose Use this secti
- Page 35 and 36: Contact investigation: Collecting,
- Page 37 and 38: Reporting Tuberculosis Detecting an
- Page 39 and 40: Prompt reporting (prior to culture
- Page 41 and 42: Use the Infectious Disease Report F
- Page 43 and 44: Data Collection Forms The following
- Page 45 and 46: Genotyping Genotyping is a useful t
- Page 47 and 48: References 1 ATS, CDC, IDSA. Contro
- Page 49 and 50: Introduction Purpose Use this secti
- Page 51 and 52: child or a person acting on behalf
- Page 53 and 54: When to Conduct Targeted Testing Al
- Page 55: Alaska Program Standards for Health
- Page 59 and 60: Table 1: NUMBERS OF FOREIGN-BORN PE
- Page 61 and 62: chest radiograph and if sputum AFB
- Page 63 and 64: Follow-up of B1 and B2 Tuberculosis
- Page 65 and 66: Evaluation of B1, B2, and B Tubercu
- Page 67 and 68: Treatment Prescribe medications as
- Page 69 and 70: 12 Centers for Disease Control and
- Page 71 and 72: Introduction Purpose Use this secti
- Page 73 and 74: Tuberculosis Classification System
- Page 75 and 76: Table 2: PERSONS AT HIGH RISK FOR T
- Page 77 and 78: Table 3: WHEN TO SUSPECT PULMONARY
- Page 79 and 80: Diagnosis of Tuberculosis Disease T
- Page 81 and 82: 1. Exposure to Infectious TB: Ask p
- Page 83 and 84: Physical Examination A physical exa
- Page 85 and 86: For more information on chest radio
- Page 87 and 88: Laboratories should report positive
- Page 89 and 90: Guidelines for preventing the trans
- Page 91 and 92: 50 CDC. National plan for reliable
- Page 93 and 94: Introduction Purpose The overall go
- Page 95 and 96: Basic Treatment Principles Follow t
- Page 97 and 98: Treatment Regimens and Dosages Use
- Page 99 and 100: Table 3: FOUR TREATMENT REGIMENS FO
- Page 101 and 102: † 4 Table 4: DOSES*OF FIRST-LINE
- Page 103 and 104: Figure 1:TREATMENT ALGORITHM FOR DR
- Page 105 and 106: a. In remote locations in Alaska, m
B Notifications<br />
CONTENTS<br />
Introduction ............................................. 4.2<br />
Purpose................................................................ 4.2<br />
Pre-arrival medical screening for tuberculosis ..... 4.2<br />
Overseas screening <strong>of</strong> applicants for<br />
immigration .......................................................... 4.4<br />
Policy ................................................................... 4.6<br />
Follow-up <strong>of</strong> B1 and B2<br />
<strong>Tuberculosis</strong> Arrivals ............................. 4.7<br />
Division <strong>of</strong> Global Migration and Quarantine<br />
forms .................................................................... 4.7<br />
Electronic disease notification process<br />
overview ............................................................... 4.7<br />
Patient follow-up .................................................. 4.8<br />
Evaluation <strong>of</strong> B1, B2, and B<br />
<strong>Tuberculosis</strong> Arrivals ............................. 4.9<br />
Evaluation activities ............................................. 4.9<br />
Treatment ........................................................... 4.11<br />
Resources and References ................. 4.12<br />
A L A S K A T U B E R C U L O S I S P R O G R A M M A N U A L B Notifications 4.1<br />
Revised November 2012